Skip to main content
. 2016 Oct 24;11(10):e0165435. doi: 10.1371/journal.pone.0165435

Fig 5. Forest plot of the odds ratios for biologics vs. placebo for anti-TNF therapy-naïve patients in maintenance studies.

Fig 5

CrI, credible interval; TNF, tumour necrosis factor. Note: Adalimumab maintenance dose: 40 mg every other week; vedolizumab maintenance dose: 300 mg every 8 weeks; golimumab maintenance dose: 100 mg every 4 weeks; infliximab maintenance dose: 5 mg/kg intravenously every 8 weeks.